167.09MMarket Cap-5659P/E (TTM)
5.260High4.290Low1.28MVolume4.290Open4.310Pre Close6.23MTurnover7.77%Turnover RatioLossP/E (Static)32.20MShares20.71052wk High0.91P/B85.53MFloat Cap2.13052wk Low--Dividend TTM16.48MShs Float20.710Historical High--Div YieldTTM22.51%Amplitude2.130Historical Low4.864Avg Price1Lot Size
Sagimet Biosciences Stock Forum
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Larger Image: tradingview.com...
$Sagimet Biosciences (SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
No comment yet